How Do GLP-1s Work: Market Trends, Brand Comparisons, and Peptide Industry Data
Published: July 12, 2026 22:02
Author: Carlos Peña
Abstract: GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) mimic incretin hormones to regulate blood glucose and appetite, driving a $40B+ market. Brand comparisons reveal efficacy advantages of dual/triple agonists versus single-target peptides. Industry data highlights supply chain bottlenecks and regulatory shifts (FDA, EMA). Key selection criteria include purity (>98%), third-party certificates of analysis (CoA), and cold-chain logistics. Market trends show rising demand for generic and research-grade peptides, emphasizing factory GMP compliance and transparent sourcing for safety and efficacy.